This website is intended for U.S. healthcare professionals only.

This website is intended for U.S. healthcare professionals only.

Next Page Icon

Indication

Cobenfy™ logo

NOW FDA APPROVED1

Introducing COBENFY: the first new class* of treatment in over 3 decades for adult patients with schizophrenia1-4

The first and only M1/M4 muscarinic agonist1,3,5*

COBENFY will be available starting October 25th

*COBENFY is a combination of xanomeline (M1/M4 muscarinic agonist) and trospium chloride (muscarinic antagonist).1

M1 and M4 receptors icon
Cobenfy on laptop screen

Register for the COBENFY National Launch Broadcast on October 25th

Cobenfy pill bottles

COBENFY will be available starting October 25th

Your patients have been waiting for a new treatment that can bring new possibilities. Now, there’s COBENFY.1

 Cobenfy  treatment video thumbnail
Megaphone icon

Read our official Press Release
for more information. 



References: 

  1. COBENFY. Prescribing Information. Bristol Myers Squibb Company; 2024.
  2. Paul SM, Yohn SE, Popiolek M, Miller AC, Felder CC. Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. Am J Psychiatry. 2022;179(9):611-627.
  3. Kaul I, Sawchak S, Walling DP, et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2024;81(8):749-756.
  4. Nuficora FC Jr, Mihaljevic M, Lee BJ, Sawa A. Clozapine as a model for antipsychotic development. Neurotherapeutics. 2017;14(3):750-761.
  5. Dean B, Bakker G, Ueda HR, Tobin AB, Brown A, Kanaan RAA. A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia. Front Cell Neurosci. 2023;17:1124333.

Cobenfy and the Cobenfy logo are trademarks of Karuna Therapeutics, Inc., a Bristol Myers Squibb company.

© 2024 Bristol-Myers Squibb Company.

1629-US-2400139  09/24